$XOMA
XOMA Royalty Corp

2017 Q4 Form 10-K Financial Statement

#000156459018004731 Filed on March 07, 2018

View on sec.gov

Income Statement

Concept 2017 Q4 2017 2016 Q4
Revenue $5.357M $52.69M $524.0K
YoY Change 922.33% 846.98% -98.91%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.710M $24.34M $5.180M
YoY Change 29.54% 32.86% 9.98%
% of Gross Profit
Research & Development $660.0K $7.875M $8.250M
YoY Change -92.0% -82.2% -39.34%
% of Gross Profit
Depreciation & Amortization $10.00K $300.0K $170.0K
YoY Change -94.12% -62.5% -19.05%
% of Gross Profit
Operating Expenses $7.371M $35.66M $13.43M
YoY Change -45.12% -46.87% -26.62%
Operating Profit -$2.010M $17.03M -$17.46M
YoY Change -88.49% -127.67% -160.75%
Interest Expense -$130.0K -$1.240M -$960.0K
YoY Change -86.46% -68.61% 57.38%
% of Operating Profit -7.28%
Other Income/Expense, Net $648.0K $1.115M -$21.00K
YoY Change -3185.71% -90.69% -99.38%
Pretax Income -$1.362M $16.26M -$17.48M
YoY Change -92.21% -130.37% -168.95%
Income Tax -$44.00K $1.662M
% Of Pretax Income 10.22%
Net Earnings -$1.318M $14.60M -$17.48M
YoY Change -92.46% -127.27% -168.95%
Net Earnings / Revenue -24.6% 27.7% -3335.88%
Basic Earnings Per Share -$0.16 $0.75 -$2.89
Diluted Earnings Per Share -$0.16 $0.73 -$2.89
COMMON SHARES
Basic Shares Outstanding 7.619M 6.047M
Diluted Shares Outstanding 7.980M

Balance Sheet

Concept 2017 Q4 2017 2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $43.50M $43.50M $25.74M
YoY Change 68.98% 69.26% -61.15%
Cash & Equivalents $43.47M $43.50M $25.74M
Short-Term Investments $0.00
Other Short-Term Assets $300.0K $300.0K $900.0K
YoY Change -66.67% -66.67% -52.63%
Inventory
Prepaid Expenses
Receivables $400.0K $400.0K $474.0K
Other Receivables $0.00 $0.00 $92.00K
Total Short-Term Assets $44.20M $44.20M $27.16M
YoY Change 62.72% 62.5% -62.39%
LONG-TERM ASSETS
Property, Plant & Equipment $83.00K $100.0K $1.036M
YoY Change -91.99% -90.0% -48.12%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $657.0K $700.0K $481.0K
YoY Change 36.59% 40.0% -27.56%
Total Long-Term Assets $740.0K $700.0K $1.517M
YoY Change -51.22% -53.33% -42.99%
TOTAL ASSETS
Total Short-Term Assets $44.20M $44.20M $27.16M
Total Long-Term Assets $740.0K $700.0K $1.517M
Total Assets $44.94M $44.90M $28.68M
YoY Change 56.69% 56.45% -61.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.679M $1.700M $5.689M
YoY Change -70.49% -70.18% -16.72%
Accrued Expenses $2.700M $2.700M $8.100M
YoY Change -66.67% -66.67% 9.46%
Deferred Revenue $798.0K
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $17.86M
YoY Change -100.0% -100.0% 202.12%
Total Short-Term Liabilities $7.422M $7.400M $32.51M
YoY Change -77.17% -77.23% 39.54%
LONG-TERM LIABILITIES
Long-Term Debt $14.57M $14.60M $25.31M
YoY Change -42.43% -42.29% -40.8%
Other Long-Term Liabilities $32.00K $17.20M $69.00K
YoY Change -53.62% -4.97% -89.75%
Total Long-Term Liabilities $14.60M $31.80M $25.38M
YoY Change -42.46% -26.73% -41.56%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.422M $7.400M $32.51M
Total Long-Term Liabilities $14.60M $31.80M $25.38M
Total Liabilities $39.15M $39.10M $75.89M
YoY Change -48.41% -48.48% -1.69%
SHAREHOLDERS EQUITY
Retained Earnings -$1.179B -$1.194B
YoY Change -1.22% 4.7%
Common Stock $1.185B $1.146B
YoY Change 3.35% 0.76%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $5.786M $5.800M -$47.21M
YoY Change
Total Liabilities & Shareholders Equity $44.94M $44.90M $28.68M
YoY Change 56.69% 56.45% -61.7%

Cashflow Statement

Concept 2017 Q4 2017 2016 Q4
OPERATING ACTIVITIES
Net Income -$1.318M $14.60M -$17.48M
YoY Change -92.46% -127.27% -168.95%
Depreciation, Depletion And Amortization $10.00K $300.0K $170.0K
YoY Change -94.12% -62.5% -19.05%
Cash From Operating Activities -$5.220M $2.686M $7.000M
YoY Change -174.57% -107.97% -75.67%
INVESTING ACTIVITIES
Capital Expenditures $10.00K $8.000K -$30.00K
YoY Change -133.33% -86.44% -175.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $1.610M $0.00
YoY Change 140.3% -100.0%
Cash From Investing Activities $20.00K $1.606M -$30.00K
YoY Change -166.67% 163.28% -100.61%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $10.16M
YoY Change 17724.56%
Debt Paid & Issued, Net $16.38M
YoY Change 137.74%
Cash From Financing Activities 920.0K 13.26M -1.840M
YoY Change -150.0% -291.04% -2400.0%
NET CHANGE
Cash From Operating Activities -5.220M 2.686M 7.000M
Cash From Investing Activities 20.00K 1.606M -30.00K
Cash From Financing Activities 920.0K 13.26M -1.840M
Net Change In Cash -4.280M 17.55M 5.130M
YoY Change -183.43% -143.85% -84.8%
FREE CASH FLOW
Cash From Operating Activities -$5.220M $2.686M $7.000M
Capital Expenditures $10.00K $8.000K -$30.00K
Free Cash Flow -$5.230M $2.678M $7.030M
YoY Change -174.4% -107.94% -75.53%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017 dei Entity Registrant Name
EntityRegistrantName
XOMA Corp
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
327000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
44195000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
83000
CY2017Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1413000
CY2017 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2017Q2 dei Entity Public Float
EntityPublicFloat
40595725
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25742000
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
852000
CY2016Q4 us-gaap Assets Current
AssetsCurrent
27160000
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1036000
CY2017 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2018Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
8329098
CY2017 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
CY2017 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2017 dei Document Type
DocumentType
10-K
CY2017 dei Amendment Flag
AmendmentFlag
false
CY2017 dei Document Period End Date
DocumentPeriodEndDate
2017-12-31
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
43471000
CY2016Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
566000
CY2017 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7619000
CY2017 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7980000
CY2016 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6021000
CY2017 dei Entity Central Index Key
EntityCentralIndexKey
0000791908
CY2017 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2017 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2017 dei Trading Symbol
TradingSymbol
XOMA
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-61558000
CY2017 us-gaap Operating Expenses
OperatingExpenses
35659000
CY2015 us-gaap Interest Expense Debt
InterestExpenseDebt
3765000
CY2015 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20620000
CY2016 us-gaap Operating Expenses
OperatingExpenses
67122000
CY2017 us-gaap Revenues
Revenues
52690000
CY2017 us-gaap Restructuring Charges
RestructuringCharges
3447000
CY2016 us-gaap Restructuring Charges
RestructuringCharges
4566000
CY2015 us-gaap Restructuring Charges
RestructuringCharges
3699000
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
44234000
CY2015 us-gaap Operating Expenses
OperatingExpenses
95171000
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
-39724000
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7875000
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
24337000
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18322000
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
899000
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-20606000
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-53530000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
14596000
CY2017 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.75
CY2016 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-8.89
CY2016 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-8.89
CY2015 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.50
CY2015 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5890000
CY2015 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5890000
CY2015 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.50
CY2017 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.73
CY2016 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6021000
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
657000
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
481000
CY2016Q4 us-gaap Assets
Assets
28677000
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5689000
CY2016Q4 xoma Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
4215000
CY2017Q4 us-gaap Assets
Assets
44935000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1679000
CY2017Q4 xoma Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
2545000
CY2016 us-gaap Revenues
Revenues
5564000
CY2015 us-gaap Revenues
Revenues
55447000
CY2017 us-gaap License And Services Revenue
LicenseAndServicesRevenue
52311000
CY2017 us-gaap Contracts Revenue
ContractsRevenue
379000
CY2016 us-gaap Contracts Revenue
ContractsRevenue
2268000
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
70852000
CY2015 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
500000
CY2017Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
4500000
CY2016Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
17855000
CY2016Q4 us-gaap Interest Payable Current
InterestPayableCurrent
254000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
32506000
CY2016Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
18000000
CY2017Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
14572000
CY2016Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
25312000
CY2016Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
69000
CY2016Q4 us-gaap Liabilities
Liabilities
75887000
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
46000
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1146357000
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1193613000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
-47210000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
28677000
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.05
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0075
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6114145
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6114145
CY2016 us-gaap License And Services Revenue
LicenseAndServicesRevenue
3296000
CY2015 us-gaap License And Services Revenue
LicenseAndServicesRevenue
49064000
CY2015 us-gaap Contracts Revenue
ContractsRevenue
6383000
CY2017 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
1115000
CY2016 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
1510000
CY2015 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9727000
CY2016 us-gaap Interest Expense Debt
InterestExpenseDebt
3946000
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
17031000
CY2015 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-17812000
CY2016 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-10464000
CY2015 xoma Increases Decreases To Additional Paid In Capital Warrant Issued
IncreasesDecreasesToAdditionalPaidInCapitalWarrantIssued
450000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
-2309000
CY2016 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
844000
CY2017 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9727000
CY2017Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
397000
CY2017Q4 xoma Accrued Restructuring Costs Current
AccruedRestructuringCostsCurrent
130000
CY2016Q4 xoma Accrued Restructuring Costs Current
AccruedRestructuringCostsCurrent
3594000
CY2017Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
1637000
CY2017Q4 us-gaap Interest Payable Current
InterestPayableCurrent
18000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7422000
CY2017Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
17123000
CY2017Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
32000
CY2017Q4 us-gaap Liabilities
Liabilities
39149000
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
62000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1184783000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1179059000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
5786000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
44935000
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.05
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
5003
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
5003
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0075
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
277333332
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
277333332
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8249158
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8249158
CY2017 us-gaap Interest Expense Debt
InterestExpenseDebt
1238000
CY2017 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-650000
CY2015 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-429000
CY2015 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
5500000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
16258000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-53530000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-20606000
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1662000
CY2017 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
5714000
CY2016 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-53530000
CY2015 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-20606000
CY2017 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
5810000
CY2016 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-53530000
CY2015 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-20606000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
3099000
CY2015 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1467000
CY2015 xoma Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
3554000
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7645000
CY2016 xoma Increases Decreases To Additional Paid In Capital Warrant Issued
IncreasesDecreasesToAdditionalPaidInCapitalWarrantIssued
97000
CY2016 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
43000
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
658000
CY2017 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
532000
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7301000
CY2017 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments
StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments
20019000
CY2017 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
9890000
CY2017 xoma License Fee Recognized Related To Repayment Of Principal And Accrued Interest Under Loan
LicenseFeeRecognizedRelatedToRepaymentOfPrincipalAndAccruedInterestUnderLoan
14346000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
7301000
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
7645000
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
9727000
CY2017 xoma Defined Contribution Plan Issuance Of Common Stock For Services Or Claims
DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims
506000
CY2016 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
331000
CY2015 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
380000
CY2017 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-363000
CY2016 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
15694000
CY2015 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
356000
CY2016 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-33689000
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-30892000
CY2015 us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
4862000
CY2016 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
612000
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
4450000
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
10160000
CY2016 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
57000
CY2015 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
171000
CY2015 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1000
CY2015 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
20000000
CY2015 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
512000
CY2016 xoma Defined Contribution Plan Issuance Of Common Stock For Services Or Claims
DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims
785000
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
13801000
CY2015 xoma Defined Contribution Plan Issuance Of Common Stock For Services Or Claims
DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims
986000
CY2017 us-gaap Depreciation And Amortization
DepreciationAndAmortization
304000
CY2016 us-gaap Depreciation And Amortization
DepreciationAndAmortization
769000
CY2015 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1532000
CY2017 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
444000
CY2016 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1451000
CY2015 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1413000
CY2017 xoma Gain Loss On Sublease
GainLossOnSublease
-800000
CY2016 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
489000
CY2015 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
1870000
CY2017 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-1635000
CY2016 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
4000
CY2015 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
69000
CY2017 us-gaap Gain Loss On Sales Of Assets And Asset Impairment Charges
GainLossOnSalesOfAssetsAndAssetImpairmentCharges
1068000
CY2016 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
126000
CY2016 us-gaap Costmethod Investments Other Than Temporary Impairment
CostmethodInvestmentsOtherThanTemporaryImpairment
370000
CY2015 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
3505000
CY2017 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-61000
CY2016 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-116000
CY2015 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-57000
CY2017 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-169000
CY2016 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-3532000
CY2015 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
761000
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-106000
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1034000
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
28000
CY2017 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-6554000
CY2016 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-3938000
CY2015 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2080000
CY2017 us-gaap Increase Decrease In Restructuring Reserve
IncreaseDecreaseInRestructuringReserve
-3464000
CY2016 us-gaap Increase Decrease In Restructuring Reserve
IncreaseDecreaseInRestructuringReserve
3135000
CY2015 us-gaap Increase Decrease In Restructuring Reserve
IncreaseDecreaseInRestructuringReserve
459000
CY2017 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
272000
CY2017 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
1637000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
2686000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8000
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
59000
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
430000
CY2017 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
1614000
CY2016 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
49000
CY2015 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
18000
CY2016 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
622000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
1606000
CY2017 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
20019000
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1550000
CY2015 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
363000
CY2017 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
16380000
CY2016 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
6890000
CY2015 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
6128000
CY2017 xoma End Of Term Fee Paid To Lender
EndOfTermFeePaidToLender
1150000
CY2017 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
51000
CY2016 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
109000
CY2015 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
41000
CY2017 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
890000
CY2015 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
53000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
13258000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-6942000
CY2017 us-gaap Effect Of Exchange Rate On Cash Continuing Operations
EffectOfExchangeRateOnCashContinuingOperations
179000
CY2016 us-gaap Effect Of Exchange Rate On Cash Continuing Operations
EffectOfExchangeRateOnCashContinuingOperations
-6000
CY2015 us-gaap Effect Of Exchange Rate On Cash Continuing Operations
EffectOfExchangeRateOnCashContinuingOperations
-37000
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
17729000
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-40025000
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-12678000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
65767000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
78445000
CY2017 us-gaap Interest Paid
InterestPaid
545000
CY2016 us-gaap Interest Paid
InterestPaid
2142000
CY2015 us-gaap Interest Paid
InterestPaid
1927000
CY2015 us-gaap Transfer To Investments
TransferToInvestments
496000
CY2017 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
45000
CY2015 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
323000
CY2015 xoma Reclassification Of Contingent Warrant Liability To Equity Exercise Of Warrants
ReclassificationOfContingentWarrantLiabilityToEquityExerciseOfWarrants
-3552000
CY2015 xoma Issuance Of Warrant Liabilities
IssuanceOfWarrantLiabilities
450000
CY2017 xoma Interest Added Principal Balances Long Term Debt
InterestAddedPrincipalBalancesLongTermDebt
487000
CY2016 xoma Interest Added Principal Balances Long Term Debt
InterestAddedPrincipalBalancesLongTermDebt
402000
CY2015 xoma Interest Added Principal Balances Long Term Debt
InterestAddedPrincipalBalancesLongTermDebt
327000
CY2017 xoma Noncash Or Part Noncash Exchange Of Loan Payable For License Agreement
NoncashOrPartNoncashExchangeOfLoanPayableForLicenseAgreement
14346000
CY2017 us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1. Description of Business</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">XOMA Corporation (referred to as &#8220;XOMA&#8221; or the &#8220;Company&#8221;), a Delaware corporation, has a long history of discovering and developing innovative therapeutics derived from its unique platform of antibody technologies. Over the Company&#8217;s 37 year history, it built an extensive portfolio of fully-funded programs by advancing product candidates into the earlier stages of development and then licensing them to licensees who assumed the responsibilities of later stage development, approval and commercialization. Fully-funded programs are those for which the Company&#8217;s partners pay all of the development and commercialization costs. As licensees advance these programs, the Company is eligible for potential milestone and royalty payments.&nbsp;&nbsp;&nbsp;&nbsp; </p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2017, the Company transformed its strategy to become a royalty aggregator with a focus on expanding its portfolio of fully-funded programs by out-licensing internally developed product candidates and acquiring potential milestone and royalty revenue streams on additional product candidates. The Company combined its royalty-aggregator model with a significantly reduced corporate cost structure to further build value for its shareholders. The Company expects that a significant portion of future revenue will be based on payments it may receive for milestones and royalties related to these programs. </p></div>
CY2017 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to, those related to contingent warrant liabilities, revenue recognition, debt amendments, long-lived assets, restructuring liabilities, legal contingencies, and stock-based compensation. The Company bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ significantly from these estimates, such as the Company&#8217;s billing under government contracts and the Company&#8217;s accrual for clinical trial expenses. Under the Company&#8217;s contracts with the National Institute of Allergy and Infectious Diseases (&#8220;NIAID&#8221;), a part of the National Institutes of Health (&#8220;NIH&#8221;), the Company bills using NIH provisional rates and thus is subject to future audits at the discretion of NIAID&#8217;s contracting office. These audits can result in an adjustment to revenue previously reported which potentially could be significant. In March 2016, the Company effected the novation of its remaining active contract with NIAID to Ology Bioservices, Inc. (&#8220;Ology Bioservices&#8221;) (formerly known as Nanotherapeutics, Inc.) (see Note 6). The billings made prior to the effective date of the novation of such contract are still subject to future audits, which may result in significant adjustments to reported revenues. </p></div>
CY2017 us-gaap Revenue Recognition Deferred Revenue
RevenueRecognitionDeferredRevenue
<div> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Sale of Future Revenue Streams</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The Company has sold its rights to receive certain milestones and royalties on product sales. In the circumstance where the Company has sold its rights to future milestones and royalties under a license agreement and also maintains limited continuing involvement in the arrangement (but not significant continuing involvement in the generation of the cash flows that are due to the purchaser), the Company defers recognition of the proceeds it receives for the milestone or royalty stream and recognizes such deferred revenue as contract and other revenue over the life of the underlying license agreement. The Company recognizes this revenue under the "units-of-revenue" method. Under this method, amortization for a reporting period is calculated by computing a ratio of the proceeds received from the purchaser to the total payments expected to be made to the purchaser over the term of the agreement, and then applying that ratio to the period&#8217;s cash payment.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Estimating the total payments expected to be received by the purchaser over the term of such arrangements requires management to use subjective estimates and assumptions. Changes to the Company&#8217;s estimate of the payments expected to be made to the purchaser over the term of such arrangements could have a material effect on the amount of revenues recognized in any particular period.</p></div>
CY2015Q4 us-gaap Contractual Obligation
ContractualObligation
0
CY2017Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
8600000
CY2016Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
4200000
CY2017Q4 xoma Equipment And Furniture Gross
EquipmentAndFurnitureGross
124000
CY2016Q4 xoma Equipment And Furniture Gross
EquipmentAndFurnitureGross
14023000
CY2016Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
554000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
124000
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
14577000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
41000
CY2016 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00
CY2016Q4 us-gaap Contractual Obligation
ContractualObligation
0
CY2015 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00
CY2017Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
26367000
CY2016Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
53557000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
4701000
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
123672000
CY2017 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
200000
CY2016 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
200000
CY2017Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2016 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
0
CY2015 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
0
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
13541000
CY2017 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
300000
CY2016 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
800000
CY2015 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1500000
CY2017 xoma Equipment Sold And Disposed During Period
EquipmentSoldAndDisposedDuringPeriod
400000
CY2017Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
141000
CY2016Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1582000
CY2016Q4 xoma Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
458000
CY2017Q4 xoma Accrued Incentive Compensation
AccruedIncentiveCompensation
229000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
431000
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
385000
CY2017Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
765000
CY2016Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
707000
CY2017Q4 xoma Liability Related To Sublease
LiabilityRelatedToSublease
800000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
179000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1083000
CY2017 xoma Performance Deliverable Period For License And Transfer Of Technology And Knowhow
PerformanceDeliverablePeriodForLicenseAndTransferOfTechnologyAndKnowhow
P60D
CY2015 xoma Upfront Fee Recognized As Revenue
UpfrontFeeRecognizedAsRevenue
5000000
CY2015Q4 xoma Accrued Restructuring Costs Current
AccruedRestructuringCostsCurrent
459000
CY2016 us-gaap Restructuring Reserve Settled Without Cash2
RestructuringReserveSettledWithoutCash2
817000
CY2016 us-gaap Payments For Restructuring
PaymentsForRestructuring
614000
CY2017 us-gaap Payments For Restructuring
PaymentsForRestructuring
6911000
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2017 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
1649000
CY2017 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
13000
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
CY2015 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
CY2016 xoma Effective Income Tax Rate Reconciliation Warrant Valuation Percent
EffectiveIncomeTaxRateReconciliationWarrantValuationPercent
0.07
CY2015 xoma Effective Income Tax Rate Reconciliation Warrant Valuation Percent
EffectiveIncomeTaxRateReconciliationWarrantValuationPercent
0.29
CY2017 xoma Effective Income Tax Rate Reconciliation Stock Compensation And Other Permanent Differences Percent
EffectiveIncomeTaxRateReconciliationStockCompensationAndOtherPermanentDifferencesPercent
0.06
CY2015 xoma Effective Income Tax Rate Reconciliation Stock Compensation And Other Permanent Differences Percent
EffectiveIncomeTaxRateReconciliationStockCompensationAndOtherPermanentDifferencesPercent
-0.01
CY2017 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.04
CY2016 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
-0.02
CY2015 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.14
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
1.28
CY2017 us-gaap Effective Income Tax Rate Reconciliation Deductions
EffectiveIncomeTaxRateReconciliationDeductions
8.68
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-10.22
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.43
CY2015 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.48
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.10
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
12225000
CY2016Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
25297000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3680000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
7099000
CY2017Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
3928000
CY2016Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
6577000
CY2017Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
883000
CY2016Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1724000
CY2016 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
592000
CY2015 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
2687000
CY2017 xoma Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions
-3705000
CY2016 xoma Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions
-1633000
CY2015 xoma Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions
1476000
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
5501000
CY2017 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.50
CY2017 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
18000
CY2016 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
18000
CY2015 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
18000
CY2017 xoma Defined Contribution Plan Maximum Annual Contribution Per Employee Over50 Years Old Amount
DefinedContributionPlanMaximumAnnualContributionPerEmployeeOver50YearsOldAmount
24000
CY2016 xoma Defined Contribution Plan Maximum Annual Contribution Per Employee Over50 Years Old Amount
DefinedContributionPlanMaximumAnnualContributionPerEmployeeOver50YearsOldAmount
24000
CY2015 xoma Defined Contribution Plan Maximum Annual Contribution Per Employee Over50 Years Old Amount
DefinedContributionPlanMaximumAnnualContributionPerEmployeeOver50YearsOldAmount
24000
CY2017 xoma Defined Contribution Plan Age Required For Catch Up Contribution Minimum
DefinedContributionPlanAgeRequiredForCatchUpContributionMinimum
P50Y
CY2016 xoma Defined Contribution Plan Age Required For Catch Up Contribution Minimum
DefinedContributionPlanAgeRequiredForCatchUpContributionMinimum
P50Y
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
51784000
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
217926000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
51784000
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
217926000
CY2017 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-166100000
CY2016 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
8200000
CY2015 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
19600000
CY2017 xoma Tax Cuts And Jobs Act Of2017 Change In Tax Rate Income Tax Expense Benefit
TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit
72700000
CY2015 xoma Defined Contribution Plan Age Required For Catch Up Contribution Minimum
DefinedContributionPlanAgeRequiredForCatchUpContributionMinimum
P50Y
CY2017 xoma Defined Contribution Plan Employer Matching Contribution Percent Of Employer Salary Deferred Maximum
DefinedContributionPlanEmployerMatchingContributionPercentOfEmployerSalaryDeferredMaximum
0.50
CY2017 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
0
CY2016 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
500000
CY2015 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
800000
CY2016 xoma Defined Contribution Plan Cost Recognized And Paid Through Issuance Of Common Shares Percentage
DefinedContributionPlanCostRecognizedAndPaidThroughIssuanceOfCommonSharesPercentage
1.00
CY2015 xoma Defined Contribution Plan Cost Recognized And Paid Through Issuance Of Common Shares Percentage
DefinedContributionPlanCostRecognizedAndPaidThroughIssuanceOfCommonSharesPercentage
1.00
CY2017Q4 xoma Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares To Be Issued Upon Exercise Of Options And Rs Us Outstanding
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesToBeIssuedUponExerciseOfOptionsAndRSUsOutstanding
1641492
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7301000
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7645000
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4818000
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1442000
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1510000
CY2017 xoma Deemed Dividends On Convertible Preferred Stock
DeemedDividendsOnConvertiblePreferredStock
5603000
CY2017 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
3279000
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
8625000
CY2017 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Diluted
UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
-96000
CY2017 xoma Incremental Common Shares Attributable To Dilutive Effect Of Stock Options
IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptions
360000
CY2017 xoma Incremental Common Shares Attributable To Dilutive Effect Of Warrants
IncrementalCommonSharesAttributableToDilutiveEffectOfWarrants
1000
CY2017Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
24800000
CY2017Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
17312
CY2016Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
498556
CY2016Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
8249
CY2016Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
15.40
CY2015Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
9666000
CY2014Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
5503000
CY2017 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
581000
CY2016Q1 xoma Exercisable Period Of Warrants
ExercisablePeriodOfWarrants
P5Y
CY2016Q1 xoma Common Stock Warrants Expiration Date
CommonStockWarrantsExpirationDate
2021-02
CY2016Q1 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
100000
CY2017Q4 xoma Contractual Obligation Estimated Milestone Payments
ContractualObligationEstimatedMilestonePayments
15500000
CY2017 xoma Lessee Leasing Arrangements Operating Leases Expiry Month And Year
LesseeLeasingArrangementsOperatingLeasesExpiryMonthAndYear
2023-04
CY2017Q4 xoma Operating Leases Number Of Successive Renewal Options
OperatingLeasesNumberOfSuccessiveRenewalOptions
2
CY2017 us-gaap Lessee Leasing Arrangements Operating Leases Renewal Term
LesseeLeasingArrangementsOperatingLeasesRenewalTerm
P5Y
CY2017Q3 us-gaap Lessee Leasing Arrangements Operating Leases Term Of Contract
LesseeLeasingArrangementsOperatingLeasesTermOfContract
P63M
CY2017Q3 xoma Operating Lease Commencement Date
OperatingLeaseCommencementDate
2017-11-14
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
900000
CY2017Q3 xoma Lease Payments Term
LeasePaymentsTerm
2023-02
CY2017 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
2400000
CY2016 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
3800000
CY2015 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
3700000
CY2017Q4 xoma Subleased Facility Number Of Portions
SubleasedFacilityNumberOfPortions
1
CY2017Q4 xoma Operating Leases Number Of Leased Facilities
OperatingLeasesNumberOfLeasedFacilities
3
CY2017Q4 xoma Operating Leases Sublease Commencement Date
OperatingLeasesSubleaseCommencementDate
2017-12-26
CY2017Q4 xoma Operating Leases Sublease Revenue Receivable
OperatingLeasesSubleaseRevenueReceivable
5100000
CY2017Q4 xoma Operating Leases Sublease Expiry Date
OperatingLeasesSubleaseExpiryDate
2023-04
CY2017Q4 us-gaap Payments For Tenant Improvements
PaymentsForTenantImprovements
800000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
3848000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
3969000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
4117000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
3332000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
2774000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
906000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
18946000
CY2017Q4 xoma Operating Leases Future Minimum Payments Due Sublease Rentals Current
OperatingLeasesFutureMinimumPaymentsDueSubleaseRentalsCurrent
897000
CY2017Q4 xoma Operating Leases Future Minimum Payments Due Sublease Rentals Year Two
OperatingLeasesFutureMinimumPaymentsDueSubleaseRentalsYearTwo
924000
CY2017Q4 xoma Operating Leases Future Minimum Payments Due Sublease Rentals Year Three
OperatingLeasesFutureMinimumPaymentsDueSubleaseRentalsYearThree
952000
CY2017Q4 xoma Operating Leases Future Minimum Payments Due Sublease Rentals Year Four
OperatingLeasesFutureMinimumPaymentsDueSubleaseRentalsYearFour
980000
CY2017Q4 xoma Operating Leases Future Minimum Payments Due Sublease Rentals Year Five
OperatingLeasesFutureMinimumPaymentsDueSubleaseRentalsYearFive
1010000
CY2017Q4 xoma Operating Leases Future Minimum Payments Due Sublease Rentals Thereafter
OperatingLeasesFutureMinimumPaymentsDueSubleaseRentalsThereafter
340000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Future Minimum Sublease Rentals
OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals
5103000
CY2017 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2017Q1 us-gaap Revenues
Revenues
260000
CY2017Q2 us-gaap Revenues
Revenues
10890000
CY2017Q3 us-gaap Revenues
Revenues
36183000
CY2017Q4 us-gaap Revenues
Revenues
5357000
CY2017Q1 xoma Restructuring Income Charges
RestructuringIncomeCharges
-2020000
CY2017Q2 xoma Restructuring Income Charges
RestructuringIncomeCharges
-1460000
CY2017Q3 xoma Restructuring Income Charges
RestructuringIncomeCharges
29000
CY2017Q4 xoma Restructuring Income Charges
RestructuringIncomeCharges
4000
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
9160000
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
8119000
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
7562000
CY2017Q4 us-gaap Operating Expenses
OperatingExpenses
7371000
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-10920000
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
1311000
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
28650000
CY2017Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-2010000
CY2017Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
205000
CY2017Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1026000
CY2017Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-600000
CY2017Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
648000
CY2017Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10715000
CY2017Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
285000
CY2017Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
28050000
CY2017Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1362000
CY2017Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1706000
CY2017Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-44000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-10715000
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
285000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
26344000
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
-1318000
CY2017Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.37
CY2017Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.02
CY2017Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.06
CY2017Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
CY2017Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.37
CY2017Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.02
CY2017Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.98
CY2017Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
CY2016Q1 us-gaap Revenues
Revenues
3962000
CY2016Q2 us-gaap Revenues
Revenues
443000
CY2016Q3 us-gaap Revenues
Revenues
635000
CY2016Q4 us-gaap Revenues
Revenues
524000
CY2016Q1 xoma Restructuring Income Charges
RestructuringIncomeCharges
-36000
CY2016Q2 xoma Restructuring Income Charges
RestructuringIncomeCharges
21000
CY2016Q4 xoma Restructuring Income Charges
RestructuringIncomeCharges
-4551000
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
17915000
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
18482000
CY2016Q3 us-gaap Operating Expenses
OperatingExpenses
12727000
CY2016Q4 us-gaap Operating Expenses
OperatingExpenses
13432000
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-13989000
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-18018000
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-12092000
CY2016Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-17459000
CY2016Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5624000
CY2016Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2858000
CY2016Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-433000
CY2016Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-21000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-8365000
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-15160000
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-12525000
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
-17480000
CY2016Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.40
CY2016Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.52
CY2016Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.08
CY2016Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.89
CY2016Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.40
CY2016Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.52
CY2016Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.08
CY2016Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.89

Files In Submission

Name View Source Status
0001564590-18-004731-index-headers.html Edgar Link pending
0001564590-18-004731-index.html Edgar Link pending
0001564590-18-004731.txt Edgar Link pending
0001564590-18-004731-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g2018030718173179143009.jpg Edgar Link pending
g2018030718173565043010.jpg Edgar Link pending
g2018030718173574444384.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
xoma-10k_20171231.htm Edgar Link pending
xoma-20171231.xml Edgar Link completed
xoma-20171231.xsd Edgar Link pending
xoma-20171231_cal.xml Edgar Link unprocessable
xoma-20171231_def.xml Edgar Link unprocessable
xoma-20171231_lab.xml Edgar Link unprocessable
xoma-20171231_pre.xml Edgar Link unprocessable
xoma-ex1031_610.htm Edgar Link pending
xoma-ex1041_608.htm Edgar Link pending
xoma-ex1053_609.htm Edgar Link pending
xoma-ex1065_606.htm Edgar Link pending
xoma-ex1066_607.htm Edgar Link pending
xoma-ex211_10.htm Edgar Link pending
xoma-ex231_9.htm Edgar Link pending
xoma-ex311_8.htm Edgar Link pending
xoma-ex312_6.htm Edgar Link pending
xoma-ex321_7.htm Edgar Link pending